What is Anoro?
Anoro is a prescription medication used to treat chronic obstructive pulmonary disease (COPD). The medication is a combination of umeclidinium, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta-agonist. Together, these two active ingredients work to relax the airways and improve breathing in individuals suffering from COPD.
Anoro is typically administered as a once-daily inhalation powder and should only be used as directed by a healthcare provider. It is not recommended for use in individuals under the age of 18 or for the treatment of acute bronchospasm.
As with any medication, there are potential side effects to be aware of when taking Anoro. These may include headache, nausea, diarrhea, dry mouth, cough, and throat irritation. In some cases, more serious side effects such as allergic reactions or increased risk of pneumonia may occur.
If you are currently taking Anoro or are considering it as a treatment option, it is important to speak with your healthcare provider to determine if it is right for you. Your healthcare provider will be able to assess your individual needs and recommend the best course of treatment for your specific condition.
Frequently Asked Questions about anoro
Once-daily ANORO is a prescription medicine used long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and to reduce the number of flare-ups. ANORO is not for asthma.
ANORO and ELLIPTA are trademarks of the GSK group of companies.
ANORO contains 2 medicines (bronchodilators) that work together to relax smooth muscles around airways and open air passages in the lungs, making it easier to breathe.
Is Anoro Ellipta (umeclidinium / vilanterol) a steroid? No, Anoro Ellipta (umeclidinium / vilanterol) is not a steroid. It's a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA). Both medications work together to help you breathe easier.
ANORO can cause serious side effects, including: COPD symptoms that get worse over time. If this happens, do not increase your dose of ANORO; instead, call your healthcare provider.
Costs. Anoro and Trelegy are both brand-name drugs. There are currently no generic forms of either drug. Brand-name medications usually cost more than generics.
Anoro ellipta was approved by the FDA for maintenance treatment of airflow obstruction in patients with COPD in December 2013.
Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators.
ANORO can cause serious side effects, including: COPD symptoms that get worse over time. If this happens, do not increase your dose of ANORO; instead, call your healthcare provider.
In clinical studies, Anoro improved lung function more than either of the drug's active ingredients (umeclidinium or vilanterol) when taken alone.
Anoro Ellipta works as a preventative medicine, so it will only be effective for as long as you are using it. Unless you are told to stop using Anoro Ellipta by your doctor, continue its use or your symptoms might return. Your doctor will change your medicines as needed.
The results showed that Trelegy was more effective for reducing flare-ups and improving lung function compared to the two medicines in Anoro. Trelegy reduced flare-ups by 25% compared to Anoro over one-year, a significant effect.
This is a brand name drug and a generic may be available. The average cost for 1 Inhaler, 60 blisters of 62.5mcg/25mcg each, is $665.99. You can buy Anoro Ellipta at the discounted price of $469.16 by using the WebMDRx coupon, a savings of 30%.
Anoro Ellipta works as a preventative medicine, so it will only be effective for as long as you are using it. Unless you are told to stop using Anoro Ellipta by your doctor, continue its use or your symptoms might return. Your doctor will change your medicines as needed.
Trelegy has been shown in clinical studies to offer an advantage over Anoro to patients with worsening COPD symptoms.
